Log In
Print
BCIQ
Print
Print this Print this
 

Sym006

  Manage Alerts
Collapse Summary General Information
Company Symphogen A/S
DescriptionRecombinant polyclonal antibody against Pseudomonas aeruginosa infections
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationPseudomonas
Indication DetailsTreat pseudomonas infection
Regulatory Designation

Partner

Meiji Seika Pharma Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today